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Abstract 
 
Introduction 
External Beam Radiotherapy (EBRT) is a recognised intervention for symptomatic 
pain relief from bone metastases. Pain flare is a reported EBRT toxicity, described in 
16-41% of steroid-naïve patients. This study aimed to determine incidence and 
duration of pain flare amongst patients within one Oncology Centre. 
 
Methods 
Patients receiving EBRT for bone metastases were recruited to a prospective cohort 
study. Baseline pain scores and a daily pain/analgesia diary were recorded during 
EBRT and for 14days thereafter. Pain flare was defined as a two-point increase on a 
pain scale or 25% increase in analgesia intake, with a return to baseline. 
 
Results 
Of the thirty-two participants, 69% (n=22) completed the diary. 41% (n=9) patients 
experienced pain flare, the median duration being 3 days. Of the evaluable patients, 
55% (n=12) were male, 45% (n=9) female. The median age was 73years, (range 40-
83). The common primary sites of disease were Breast (32%) and Prostate (32%), 
with other sites making up the remaining 36%. The most frequent EBRT site was the 
spine (63%), with other treatment sites including pelvis (23%) and extremities (14%). 
EBRT regimes were restricted to 20Gy in 5 treatments, received by 32% (n=7) of 
patients and 8Gy in 1 treatment (68% (n=14)). Of these two regimes, pain flare was 
reported by 29% and 47% respectively. 
 
Conclusion 
Pain flare is a common toxicity of EBRT for bone metastases. Taking the small sample 
size into consideration, the incidence and duration of pain flare in patients within this 
single-centre study are comparable with those found in international studies. 
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Introduction 
 
Cancer incidence is rising due to longer life expectancy, and an improvement in 
systemic anti-cancer therapy (SACT) has led to greater numbers of patients living 
longer with metastatic disease1. In particular, bone metastases are a frequently 
occurring complication of many cancers, predominantly breast, prostate and lung, and 
are known to be experienced by approximately 70% of patients2. These can lead to 
poor quality of life (QoL), with patients experiencing many symptoms, including 
pathological fractures, hypercalcaemia and metastatic spinal cord compression 
(MSCC), some of which may require surgical intervention3-5. The main systemic 
management options for bone cancer are SACT (including bisphosphonates), surgery, 
chemotherapy and hormone manipulation, supported by analgesia. External Beam 
Radiotherapy (EBRT) provides a useful local treatment for pain relief. EBRT is widely 
used with approximately 23,000 episodes delivered due to metastatic bone cancer in 
England in 20136. It has been evidenced to provide symptomatic relief and loco-
regional control for approximately 50-80% of patients, and complete response for 30-
50%7. 
 
Toxicities due to palliative EBRT vary, with patients experiencing erythema, fatigue 
and local side effects, e.g. nausea, diarrhoea. Furthermore, prospective studies have 
recognised that pain flare may be observed in up to 41% of patients in the period 
immediately post-treatment9. Pain flare is identified as a transitory increase of pain 
experienced within the irradiated site, and is thought to be caused by oedema of the 
periosteum compressing on nerves or the release of inflammatory cytokines10. Flare 
is generally quantified as i) an increase of 2 points on a numerical rating scale (NRS) 
with no increase in analgesia, or ii) a 25% increase in analgesia to maintain the 
previous pain levels8,9.  
 
Limited evidence evaluating incidence of pain flare is available from within the 
literature, thus a corresponding pilot study was undertaken to identify and evaluate the 
experience within one UK Oncology Centre and subsequently compare the results 
with published literature. 
 
Materials and Methods 
Ethical approval was obtained from the Regional Ethics Committee (REC) and from 
the participating NHS Trust to undertake the study. 
 
A prospective cohort study was undertaken with participation confined to one 
Oncology Centre within a 9 month period from December 2015 to August 2016. 
Patients were aged 18 years or over and capable of providing informed consent. A 
histological-proven diagnosis of any primary cancer or haematological malignancy 
was required, with radiologically-proven osseous metastases. Patients who were 
prescribed either 8Gy in a single treatment or 20Gy in five fractions of EBRT were 
eligible, conforming to the protocol within the Oncology Centre for prescription of 
EBRT to painful lesions.  Participants were required to be assessed as having a 
performance status (PS) of 0-3 inclusive using the criteria developed by the Eastern 
Cooperative Oncology Group11.  Due to differing EBRT protocols and treatment intent, 
patients prescribed EBRT for pathological fracture of a bone, MSCC, an area 
previously irradiated or non-proven osseous metastases were excluded.  
 
Prior to EBRT, a questionnaire was completed using the Oncology Centre’s electronic 
patient records and treatment management system, to ascertain baseline 
demographic data. The variables within this included gender, age, primary disease 
site, site and prescribed dose of current EBRT and any previous EBRT received. 
Baseline pain burden was assessed using the Brief Pain Inventory (BPI) and regular 
analgesia consumption registered12. The patient was provided with a pain diary, with 
written and verbal instructions regarding its completion, to record the worst pain score 
experienced each day on an NRS and any supplementary analgesia required. The 
diary was completed daily from the first day of treatment until 14 days following 
completion of EBRT. Patients were provided with a postage-paid envelope in which to 
return the diary and were contacted by telephone towards the end of the diary period 
to encourage them to do so. 
 
Chow’s definition of pain flare was used by the majority of the published studies, and 
was thus used within this study to enable comparison of results8. Consequently, pain 
flare was defined as a 2 point increase in pain on an 11 point NRS of 0 – 10 or a 25% 
increase in analgesia to maintain the previous pain level, with return to baseline 
following the flare. 
 
Data from the completed diaries were collected on an excel® (Microsoft, Redmond, 
WA) spreadsheet to ascertain incidence of pain flare amongst the study population. 
Descriptive statistics were gathered to report percentages of the population 
experiencing pain flare; this was compared directly with the published studies. 
Demographic data was evaluated to ascertain statistical significance in gender, 
primary disease site, dose received, etc. Pearson’s chi-square analysis was used to 
test any associations between these variables, with the approximate P-value giving 
the probability of the observed differences happening by chance. A statistical 
significance threshold was agreed at 5%. Yates’ continuity correction factor was 
applied to improve the accuracy if the cell values were less than 5. Incomplete data 
was analysed and assessed for suitability to be included in the overall results. 
Inclusion was dependent on the aspects of the data missing, for example, no indication 
on the NRS may be negated if the analgesia record was complete as this included the 
pain level at the time the medication is taken. Non-completion of the diary led to 
exclusion of the participant and therefore omission from the overall analysis.           
 
Results 
Thirty two patients were recruited into the study between December 2015 and August 
2016, of which 47% (n=15) were males and 53% (n=17) were females. Of those 
enrolled, 69% (n=22) completed their daily pain diary to provide evaluable data which 
has been statistically analysed. Table 1 demonstrates the relevant data of the 
appraisable participants. Reasons for exclusion from the study included decline in 
patient condition or death during the study period, patient withdrawal from the study, 
non-return of the diary or insufficient data to allow for evaluation. 
 
Daily pain levels were recorded by the participants using the BPI. Pain flare incidence 
was calculated, with the independent variables of pain experiences in the evaluated 
group indicated in Table 2. Ten of the evaluable patients experienced an increase of 
at least 2 points on the pain scale at some stage in their study period, however, using 
the Chow definition, 41% (n=9) of these actually experienced pain flare8. The 10th 
patient’s pain did not revert back to the original level and thus cannot be recorded as 
a flare. Severity and duration varied between participants. Pain flare occurred within 
the first 5 days in all of the patients (100%). 3 patients experienced intermittent pain 
flare and therefore provided more than one set of data, resulting in 13 reported 
episodes of flare in total. The mean duration of flare was 3 days (range 1-10 days). 
 
Data was gathered regarding systemic and steroidal treatments, radiation dose and 
site as indicated in Table 2. The analysis of patients also receiving SACT, including 
Abiraterone and Tyrosine-kinase inhibitors, and steroid treatment was introduced part-
way through the study period. Retrospective data was gathered where possible for 
early participants; however it was not possible to elicit this information from some 
annotations and records, reducing quantifiable data.  
 
The age range of the evaluable patients within this study was between 40 and 83 years 
(median age 73 years). Of those experiencing pain flare, the range was 43-82 years, 
with an overall mean age of 67.4 years. Further analysis indicates that the male age 
range was 57-82 years, with a mean age of 73.8 years; the female population range 
was 43-72, the mean being 59.5 years. There was no statistical difference between 
patients who did or did not experience pain flare for the majority of variables, including 
gender, age range, primary cancer site, EBRT site, EBRT dose or SACT when using 
a significance of p<0.05. However, using Fisher’s chi-square test for independence, a 
significant difference was found in pain flare experience between those who did and 
did not receive steroids during their evaluation period, with a probability (p-value) of 
0.0253 (p<0.05). When the Yates correction factor was applied due to the small cell 
values, the p-value was recalculated at 0.0935; the statistical significance cannot be 
confirmed. The calculations do not take into consideration the unknown steroidal 
status of 7 patients.  
 
 
Discussion 
This study provided further evidence that pain flare is experienced by patients 
receiving EBRT to secondary bone cancer, with 41% (n=9/32) of evaluable patients in 
the Oncology Centre reporting an increase in pain which conformed to the definition 
used8. The overall result is equivalent to the highest within the range identified in the 
reviewed publications (16-41%), although it is acknowledged that the results in our 
study may have been affected by imprecise patient annotation within the research tool 
and also the inclusion of participants who were also receiving SACT and steroid 
treatment. There is a wide range of results within published articles; however this may 
be due to inconsistent definition of pain flare. The definition used within our study is 
recognised to be the standard8. Furthermore, differing radiation dose schedules, pain 
flare measurement timescales and the allowance of steroids and SACT may account 
for some of the differences. The local incidence result may be seen as generally 
comparable, taking into consideration the small sample and restricted EBRT dose 
regimes allowed within the study criteria. 
 
The timescale for recruitment was limited to a 9 month period, in which 32 patients 
were recruited. This study number is low compared to published data; however these 
recruited over longer periods of time or from more than one Oncology Centre. Other 
factors affecting enrolment included fluctuation in the suitable population, thus limiting 
the availability of potential participants, and having just one member of staff recruiting 
to the study. Low accrual and high attrition rates within palliative clinical research are 
common, with barriers to recruiting participants including the patient or family 
perception of the onus of participating, patient PS and limited life expectancy, amongst 
others13. Such issues were identified within the recruitment period of this study, with 
further concerns including poor cognition of the study concept and lack of family 
support. Research within the palliative medicine setting requires careful consideration 
and management of the participants; there should be no notion of coercion or pressure 
to participate. As a result, gatekeeping by health care professionals is recognised as 
negatively impacting on  palliative study recruitment14 and this research acknowledges 
an element of this occurred when  assessing the potential recruits’ suitability to 
participate;  
 
Statistical analysis of gender, age, primary disease site, EBRT dose and EBRT site 
has not identified any patient groups which may be at risk of pain flare; this concurs 
with published studies with the exception of one which reported Breast cancer patients 
to have a greater likelihood of experiencing an exacerbation of pain9. Initial statistical 
analysis showed a significant difference between patients who did or did not receive 
steroids during EBRT. The Yates correction factor was applied which indicated that 
the result could not be confirmed as statistically significant15. Furthermore, the details 
regarding steroids could not be ascertained in 32% (n=7/22) of patients. No patients 
were purposefully prescribed prophylactic steroids, and levels of Dexamethasone 
taken were between 0.75-2mg, far less than that prescribed in the studies investigating 
this topic10, 16-19. The results are contradictory to the expectation that Dexamethasone 
may reduce the incidence of pain flare. 
 The age range of the evaluable patients within this study was between 40 and 83 
years, with flare experienced within the age range of 43-82 years. With the mean male 
age being 73.8 years, the female mean age was considerably lower at 59.5 years. 
This lower female age may be attributed to that 50% (n=2/4) patients had a primary 
Breast cancer. Over half (54%) of Breast cancer cases are diagnosed in patients under 
65 years of age, compared to Prostate cancer in which 54% of diagnoses are in men 
over 70 years of age20.  Within this study 32% (n=7/22) of the evaluable male 
population had a Prostate cancer primary, thus statistical analysis cannot be made 
between flare incidence and age. There is no link reported in the literature. 
 
Attempts were made to encourage full participation in the study, with telephone calls 
made to patients to ascertain if there were problems and to serve as a reminder to 
return the diary. However, 60% (n=6/10) of those excluded were due to non-return of 
this, with further reasons for non-inclusion comprising deterioration in condition and 
withdrawal from the study. The previously published studies all experienced similar 
attrition reasons and rates; high attrition rates are common within supportive care and 
palliative oncology research studies, with the main reason being patient withdrawal, 
mainly due to a high symptom burden, which may or may not be related to the clinical 
trial intervention21. Patients within such studies generally have a poor PS due to the 
impact of their bone metastases and general disease burden, thus it may be predicted 
there could be a proportion that deteriorate in health or unfortunately die within their 
pain diary period. Whilst patients are assessed for suitability for treatment, there are 
occasions when the rate of decline in their health may not be foreseen; furthermore 
they may be immuno-compromised due to previous or current systemic treatments, 
rendering them susceptible to infection which may impact further on their general 
health. 
 
This project was undertaken as a pilot study to ascertain potential recruitment and 
suitability of the research tool. A second phase of the study will be undertaken, with 
the intention to expand our cohort of patients by increasing the size of the research 
team and recruiting over a greater length of time. A revision of the diary may be 
considered for the subsequent study to enhance the quality and depth of data, thus 
enabling improved reporting and statistical analysis  
  
Conclusion 
Despite the relatively small sample size, the incidence and duration of pain flare in 
patients within this single-centre study are comparable with those found in similar 
international studies and the results provide further evidence to support the assertion 
that pain flare may be a recognisable toxicity following palliative EBRT for painful 
bone metastases. The findings will support the information provided to patients 
regarding potential EBRT-related toxicities during the consent process. Greater 
consideration should be paid to analgesia available to the patients, with safe 
provision of supplementary medications made in case exacerbation of pain is 
experienced. 
Future research is intended to extend our examination of this phenomenon and 
supplement our knowledge of the incidence and duration of pain flare.  
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Table 1. Demographic, clinical and treatment details of patients recruited  
 Non-evaluable patients (n 10) Evaluable patients(n 22) 
Gender 
Male   
Female 
 
30% (3) 
70% (7) 
 
55% (12) 
45% (10) 
Age (years)  
Mean +/- SD 
Median (range) 
 
62 +/- 12.99 
60 (45-88) 
 
65 +/- 14.45 
773 (40-83) 
Primary cancer site 
Breast  
Prostate  
Multiple Myeloma  
Others 
 
50% (5) 
0 
10% (1) 
40% (4) 
 
32% (7) 
32% (7) 
9% (2) 
27% (6) 
Radiation site 
Spine 
Pelvis 
Extremities 
Axial skeleton 
 
50% (5) 
10% (1) 
0  
40% (4) 
 
63% (14) 
23% (5) 
14% (3) 
0 
Radiation dose 
20Gy in 5# 
8Gy in 1# 
 
10% (1) 
90% (9) 
 
32% (7) 
68% (15) 
 
 
 
 
 
 
Table 2. Characteristics of pain experienced in evaluated patients 
 No pain flare  
(n 13) 
Pain flare  
(n 9) 
p-value 
Gender 
Male   
Female 
 
62% (8) 
38% (5) 
 
55% (5) 
45% (4) 
p=0.779 
Age range (years) 
40-49   
50-59 
60-69 
70-79 
80-89 
 
30% (4) 
8% (1) 
8% (1) 
46% (6) 
8% (1) 
 
11.1% (1) 
11.1% (1) 
22.2% (2) 
45.5% (4) 
11.1% (1) 
P=0.760 
Primary cancer site 
Breast  
Prostate  
Multiple Myeloma  
Others 
 
38% (5) 
31% (4) 
0 
31% (4) 
 
22.2% (2) 
33.3% (3) 
22.2% (2) 
22.2% (2) 
p=0.323 
Radiation site 
Spine 
 
69% (9) 
 
55% (5) 
p=0.612 
Pelvis 
Extremities 
Axial skeleton 
23% (3) 
8% (1) 
0 
22.5% (2) 
22.5% (2) 
0 
Radiation dose 
20Gy in 5# 
8Gy in 1# 
 
38% (5) 
62% (8) 
 
22% (2) 
78% (7) 
p=0.421 
Steroids 
Yes 
No 
(Unknown) 
 
8% (1) 
61% (8) 
(31% (4) ) 
 
45% (4) 
22.5% (2) 
(33.5% (3) ) 
P=0.0253 
Systemic treatments 
Yes 
No 
(Unknown) 
 
23% (3) 
62% (8) 
(15% (2) ) 
 
55.7% (5) 
22.2% (2) 
(11.1% (1) ) 
p= 0.661 
 
